Early Adoption of Cyclosporine and Recombinant Human Erythropoietin: Clinical, Economic, and Policy Issues With Emergence of High-Cost Drugs
Open Access
- 1 July 1994
- journal article
- review article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 24 (1), 33-41
- https://doi.org/10.1016/s0272-6386(12)80157-0
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in CanadaSocial Science & Medicine, 1992
- Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.BMJ, 1992
- Recombinant Erythropoietin:Orphan Product with a Silver SpoonInternational Journal of Technology Assessment in Health Care, 1992
- Blood transfusion costs: a multicenter studyTransfusion, 1991
- CyclosporineNew England Journal of Medicine, 1989
- The Effect of Cyclosporine on the Use of Hospital Resources for Kidney TransplantationNew England Journal of Medicine, 1989
- Transmission of the Human Immunodeficiency VirusNew England Journal of Medicine, 1987
- To Buy or Not to BuyNew England Journal of Medicine, 1984
- A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal TransplantationNew England Journal of Medicine, 1983
- A Comparison of Androgens for Anemia in Patients on HemodialysisNew England Journal of Medicine, 1981